Adaptimmune Therapeutics PLC — Director's Dealing 2016

Jan 4, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2016-01-01

Reporting Person: Noble James (Director, Chief Executive Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares with a nominal value of GBP0.001 per share	9972600	Direct
Ordinary Shares with a nominal value of GBP0.001 per share	1200000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to purchase Ordinary Shares	$0.1671	2024-03-31	Ordinary Shares (1335000)		Direct
Option to purchase Ordinary Shares	$0.1671	2024-04-14	Ordinary Shares (438100)		Direct
Option to purchase Ordinary Shares	$0.5308	2024-12-19	Ordinary Shares (3500000)		Direct

Footnotes

F1: Represented by 200,000 American Depositary Shares ("ADSs") held by Mr. Noble. Mr. Noble holds these Ordinary Shares in the form of ADSs. Each ADS represents six Ordinary Shares of Adaptimmune Therapeutics plc.

F2: Currently exercisable as to 915,000 Ordinary Shares and will be exercisable as to the remainder ratably in annual installments on the thirty first of March from March 31, 2016 through March 31, 2018.

F3: Currently exercisable as to 109,500 Ordinary Shares and will be exercisable as to 109,500 Ordinary Shares on each of April 14, 2016 and April 14, 2017 and as to 109,600 Ordinary Shares on April 14, 2018.

F4: Exercisable as to 875,000 Ordinary Shares on December 19, 2015 and will be exercisable as to the remainder in monthly installments of 72,900 Ordinary Shares on the nineteenth of each month from January 19, 2016 through November 19, 2018, and in one installment of 73,500 Ordinary Shares on December 19, 2018.

F5: The exercise price was converted from GBP0.112 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.

F6: The exercise price was converted from GBP0.112 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.

F7: The exercise price was converted from GBP0.3557 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.